Nanomedicine delivery framework for skeletal muscle therapies
Official title: A novel framework for nanomedicine development
Funded at University of Oklahoma · NIH-11377518 · Data updated 2026-11-12
A new framework aims to safely and efficiently deliver tiny nanoparticles carrying drugs or genetic payloads to skeletal muscle cells.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma NIH-funded |
| Lab location | 1 site (Norman, United States) |
| Project start | September 1, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $373,297 |
| NIH project number | 5R35GM150758-04 |
| Project ID | NIH-11377518 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals with muscular dystrophies or other skeletal muscle disorders who may benefit from improved drug or gene-delivery therapies in the future.
✕Less likely to help
Early-stage work may not directly benefit patients until later translational steps are completed.
What this research studies
This project focuses on creating advanced, non-viral nanoparticles that can reach muscle cells and tissues. It will also develop high-resolution imaging methods to watch how these nanoparticles move and behave inside the body. Finally, the team will measure how safe, efficient, and effective these delivery systems are in living organisms, with the goal of enabling better treatments for muscle diseases.
Why it matters
Potential benefit: If successful, patients with muscle diseases could receive more effective, targeted therapies delivered by nanoscale carriers.
How similar studies have gone: Previous nanomedicine efforts have shown promise in targeted delivery, but this project seeks a novel framework specifically for skeletal muscle delivery.
Where this research is happening
-
University of Oklahoma
Norman, United States Active
Researchers
- Principal investigator: Wilhelm, Stefan — University of Oklahoma
- Study coordinator: Wilhelm, Stefan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.